Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Krystal Biotech. The associated price target remains the same with $240.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including Krystal Biotech’s strong financial performance and strategic global expansion. The company reported better-than-expected earnings per share and revenue for the second quarter of 2025, demonstrating financial robustness with $820 million in cash reserves. This financial strength is supported by a return to revenue growth, attributed to patients resuming treatments and an expanding sales team, which is expected to further enhance revenue in the coming quarters.
Moreover, Krystal Biotech is expanding its market presence globally, with the recent approval of VYJUVEK in Japan and upcoming launches in Europe, starting with Germany and France. The company’s pipeline is also progressing well, with significant developments in oncology and aesthetic programs, and several clinical catalysts anticipated by the end of 2025. These factors collectively strengthen the long-term growth trajectory for Krystal Biotech, justifying the Buy rating.
Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Capricor Therapeutics, and Cytokinetics. According to TipRanks, Pantginis has an average return of -17.7% and a 32.06% success rate on recommended stocks.
In another report released on July 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $215.00 price target.